Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 615 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ February 3, 2021 FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma February 28, 2024 EMA Recommends Granting a Marketing Authorisation for Ivosidenib March 1, 2023 New treatment for Waldenstrom’s macroglobulinaemia in England October 1, 2022 Load more HOT NEWS How Having a Creative Outlet Helped Me Cope During Cancer Cancer Patients Get Free, Beautiful Henna Crowns From Local Artist Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... Foodie Friday: Pumpkin EVERYTHING!
